Related Experiment Video
Updated: Aug 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Atherosclerosis treatment with etofibrate retard. New perspectives]
Insights
Etofibibrate retard significantly reduced cholesterol and triglycerides in hyperlipoproteinemic patients. The drug also lowered blood glucose, uric acid, and blood pressure, demonstrating broad efficacy with excellent tolerance.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Abstract:
In a multicentric general-practice-study 2504 hyperlipoproteinemic patients were treated with etofibrate retard for 4 weeks. The drug was administered once daily in the evening. A highly significant decrease of the mean values of cholesterol around 18.4% and 27.6% resp., and of the mean triglycerides between 31.3% and 16.5% resp. were observed. The atherogenic index was reduced by 28%. The simultaneous, highly significant reduction of blood glucose and of uric acid levels as well as of blood pressure showed the comprising effects of etofibrate retard against the atherosclerosis and its risk factors. The excellent tolerance of the drug was stated by more than 99% of the patients treated.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care

